Skip to main content
. 2021 Nov 19;102(3):115597. doi: 10.1016/j.diagmicrobio.2021.115597

Fig. 4.

Fig. 4

Antibody rates for participants without seroconversion on day +40. Purple and green lines represent the participants with Rituximab treatment. The dotted line represents the days of the vaccine application (2 doses). (A) N-protein IgG evaluation. (B) S1-protein IgG evaluation (color version of figure is available online).